Depakote Birth Injury Resources Evaluating Abbott Laboratories for Potential Lawsuits Related to Birth Defects From Depakote Use
The prescription drug Depakote is currently the most prescribed branded treatment for patients with mania associated with bipolar disorder as well as for the treatment of epilepsy. Depakote is produced by Abbott Laboratories, a pharmaceutical company based in Abbott Park, North Chicago, Illinois. Currently, Abbot Laboratories is being evaluated by Depakote Birth Injury Resources (“DBIR” or DepakoteBirthInjury.com) for the high number of birth defects and birth injuries resulting from the use of Depakote by mothers during pregnancy. DBIR offers information and about the possible side effects of Depakote and legal resources for mothers whose children have sustained Depakote-related birth defects.
(PRWEB) January 7, 2011
The most popular prescription drug currently on the market for treating both epilepsy and the manic phase of bipolar disorder is the branded pharmaceutical Depakote. Following a 2009 FDA warning about the possible birth defects associated with Depakote use during pregnancy, Abbott Laboratories, the manufacturer of Depakote, is coming under increased scrutiny about the dangerous side effects of the drug. Depakote Birth Injury Resources (DBIR) are currently evaluating Abbott Laboratories for potential lawsuits regarding a correlation between Depakote taken during pregnancy and a heightened chance of severe birth injury (Source: “The Teratogenicity of Anticonvulsant Drugs“, New England Journal of Medicine, April 2001).
Depakote is estimated to have been used by over 2 million people since its first FDA approval in 1983 and is known by a host of other brand and generic names, including Depacon (valproate sodium), Depakote CP, Depakote ER, Depakote Sprinkles (dilvalproex sodium), Stavzor (valproic acid) and Depakene (valproic acid), among others. Depakote is indicated for the treatment of mania associated with bipolar disorder, and as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures. Depakote is also indicated for the prevention of migraine headaches in adults.
Depakote is produced by Abbott Laboratories, a pharmaceutical corporation whose headquarters are based in Abbott Park, North Chicago, Illinois. Abbott Laboratories was established by the physician Dr. Wallace Calvin Abbott in 1888 and currently has over 72,000 employees and operates in 130 countries worldwide. In 2008, Abbott had over $29 billion in revenue. The company’s drug portfolio includes HUMIRA (treatment for various forms of arthritis, Crohn’s Disease and severe psoriasis), Norvir (an HIV treatment), Depakote (anticonvulsant drug) and Synthroid (a synthetic thyroid hormone). Depakote was once one of Abbott’s best-selling drugs, generating nearly $1.4 billion in sales for 2008, although sales have recently declined due to generic competition. Abbott also produces a broad range of medical devices and nutritional products, including most notably the meal-replacement shake Ensure, and EAS, a system of nutritional supplements.
In December of 2009, the US Food and Drug Administration has issued a warning to health care professionals and patients about the potential increased risk of birth injuries and birth defects when valproate sodium and related products are used by mothers during pregnancy. The FDA warning centers around the risk of neural tube defects (defects of the brain and spinal cord) and other major birth defects, such as craniofacial defects (cleft palate or abnormally formed face and skull) and cardiovascular malformations (abnormally formed heart or blood vessels) in babies exposed to valproate sodium and related products during pregnancy (Source: “Birth Defects Related to Depakote and Similar Drugs“, Dec 2009, http://www.fda.gov)
Attorneys from Depakote Birth Injury Resources (DepakoteBirthInjury.com) are currently evaluating Abbott Laboratories for potential lawsuits related to birth defects. With data showing a strong link between Depakote and increase risk for birth defects, any person who is currently taking Depakote or who took Depakote during pregnancy and experienced side effects or birth defects and injury in their child is advised to seek consultation (Source: “The Teratogenicity of Anticonvulsant Drugs“, New England Journal of Medicine, April 2001). For more information about the Depakote side effects, birth defects associated with Depakote use or Depakote birth defect resources, visit DBIR at DepakoteBirthInjury.com
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/01/prweb4944804.htm